Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study

Table 3

Optimal cutoff values of predictive parameters for the CI of 40% reduction in the eGFR by X years after the initiation of IST.

Clinical parameters	X = 2 (sensitivity, specificity)	X = 3 (sensitivity, specificity)	X = 4 (sensitivity, specificity)	X = 5 (sensitivity, specificity)	X = 6 (sensitivity, specificity)	X = 7 (sensitivity, specificity)	X = 8 (sensitivity, specificity)
ΔS-suPAR (2M; pg/mL)	686.6 (1.00, 0.83)	225.6 (0.97, 0.74)	225.6 (0.97, 0.74)	225.6 (0.97, 0.74)	225.6 (0.92, 0.80)	3.4 (0.95, 0.79)	3.4 (0.95, 0.79)
u-PCR (2M; g/gCr)	3.9 (1.00, 1.00)	0.9 (0.97, 0.79)	0.9 (0.97, 0.79)	0.9 (0.97, 0.79)	0.4 (0.92, 0.80)	0.4 (0.93, 0.86)	0.4 (0.93, 0.86)
u-L-FABP (2M; μg/gCr)	27.0 (1.00, 1.00)	11.3 (0.97, 0.91)	11.3 (0.97, 0.91)	11.3 (0.97, 0.91)	4.8 (0.97, 0.68)	10.0 (0.93, 1.00)	10.0 (0.93, 1.00)
s-suPAR (2M; pg/mL)	4222.1 (1.00, 0.86)	2836.4 (0.97, 0.59)	2836.4 (0.97, 0.59)	2836.4 (0.97, 0.59)	3978.2 (0.83, 0.89)	3501.5 (0.88, 0.92)	3501.5 (0.88, 0.92)

Δs-suPAR (2M), change (Δ) in the serum soluble urokinase plasminogen activator receptor (suPAR) within 2 months of initiating immunosuppressive therapy (IST); u-PCR (2M), urinary protein-to-creatinine ratio at 2 months after initiating IST; u-L-FABP (2M), urinary liver-type fatty acid-binding protein at 2 months after initiating IST; s-suPAR (2M), serum suPAR at 2 months after initiating IST; eGFR, estimated glomerular filtration rate.